I disagree and argue the Angelman and PH results were average. The PMD were outstanding. Yes there is always a risk P3 will not be succesful. In the meantime, daybue revenue growth and the associated royalties and milestones will occur expected. Even just being accepted to progress to P3 trials add value. As will new indications to be studied.
I disagree and argue the Angelman and PH results were average....
-
- There are more pages in this discussion • 1,410 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |